Human Immunology News 5.40 October 10, 2017 | |
| |
TOP STORYAn Anti–Glypican 3/CD3 Bispecific T Cell–Redirecting Antibody for Treatment of Solid Tumors Scientists developed ERY974, a whole humanized immunoglobulin G–structured TRAB harboring a common light chain, which bispecifically binds to GPC3 and CD3. Using a mouse model with reconstituted human immune cells, they revealed that ERY974 is highly effective in killing various types of tumors that have GPC3 expression comparable to that in clinical tumors. [Sci Transl Med] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)EZH2 expression levels were determined in CD4+ T cells isolated from lupus patients and healthy controls. The epigenetic effects of EZH2 overexpression in CD4+ T cells were evaluated using a genome-wide DNA methylation approach. [Arthritis Rheumatol] Abstract Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis The role of aryl hydrocarbon receptor in human B cell development has not been investigated. Toward this end, an in vitro feeder-free human B cell developmental model system was employed using human cord blood CD34+ hematopoietic stem/progenitor cells. [J Immunol] Abstract Investigators report the pro-inflammatory effect of ImI, a well characterized conotoxin that inhibits α7 nicotinic acetylcholine receptors, on differentiated THP-1 pre-monocyte macrophages obtained by phorbol 12-myristate 13 acetate treatment. [Sci Rep] Full Article T Cell Responses in Senior Patients with Community-Acquired Pneumonia Related to Disease Severity In senior patients with community-acquired bacterial pneumonia, the authors investigated the frequencies and functions of regulatory T cells. They found that compared to age- and sex-matched healthy controls, senior pneumonia patients presented lower frequencies of Foxp3-expressing and Helios-expressing CD4+ T cells. [Exp Cell Res] Abstract The authors investigated the production of Th17-associated cytokines by peripheral blood mononuclear cells of untreated patients with hepatitis C virus (HCV), patients presenting an early virologic response after 12 weeks of treatment with interferon-α plus ribavirin with or without HCV protease inhibitors, and patients who were nonresponders to HCV therapy. [Cytokine] Full Article Human Amylin Induces CD4+Foxp3+ Regulatory T Cells in the Protection from Autoimmune Diabetes Scientists report human amylin (hA) immune-modulatory action through inducing regulatory T cells. They ex vivo-treated human peripheral blood mononuclear cells with hA for 24 hours and counted CD4+Foxp3+ regulatory T cells using flow cytometry. [Immunol Res] Abstract Investigators defined the effect of short-term and long-term Rhodospirillum rubrum L-asparaginase mutant E149R, V150P, F151T exposure on proliferation of cancer Jurkat cell line and normal human CD4+ T lymphocytes. [Cancer Med] Abstract This study assessed the activation of CD4+ and CD8+ T-lymphocytes by human insulin and human glutamate decarboxylase (GAD) in patients with type 1 or type 2 diabetes mellitus and healthy volunteers. [Endocr Connect] Abstract | Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSThe Role of Regulatory B Cells in Allergen Immunotherapy The author summarizes recent findings relevant to the topic of regulatory B cells and their potential role in allergen immunotherapy. [Curr Opin Allergy Clin Immunol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSCelyad Reports a First Complete Response in a Relapsed Refractory AML Patient in the THINK Trial Celyad announced early clinical results of the first dose-level in the hematological arm of its THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D). [Celyad] Press Release City of Hope announced that a research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., has received a $12.8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund a Phase I CAR-T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma. [City of Hope] Press Release Michael Pulsipher, MD, of the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles, along with co-principal investigator, Sung-Yun Pai, MD, of Boston Children’s Hospital, has been awarded nearly $9 million from the National Institute of Allergy and Infectious Diseases of the NIH to study a new treatment approach for babies born with severe combined immunodeficiency. [Children’s Hospital Los Angeles] Press Release CEL-SCI Corporation announced that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine, which is currently in a pivotal Phase III trial for head and neck cancer. [CEL-SCI Corporation] Press Release | |
| |
POLICY NEWSPublishers Threaten to Remove Millions of Papers from ResearchGate Millions of articles might soon disappear from ResearchGate, the world’s largest scholarly social network. Five publishers said they had formed a coalition that would start ordering ResearchGate to remove research articles from its site because they breach publishers’ copyright. [Nature News] Editorial Navajo Nation Reconsiders Ban on Genetic Research When the Navajo Nation opens its first oncology centre next year in Tuba City, Arizona, clinicians there may be able to offer a service that has been banned on tribal lands for 15 years: analyzing the DNA of Navajo tribe members to guide treatments and study the genetic roots of disease. [Nature News] Editorial Does Your State Get Its Fair Share of Federal Research Dollars? The only physicist in Congress has introduced a bill (H.R. 3763) that could rekindle a debate over how to deal with geographic disparities in the allocation of federal research funding. [ScienceInsider] Editorial Scientists Plead with Brazilian Government to Restore Funding Anxiety is growing in Brazil over the country’s collapsing research budgets. President Michel Temer had slashed funding for science by 44% in March and has proposed additional decreases for 2018 — even as some science institutes run out of money for basic needs, such as paying electricity bills. The 2017 science budget, at 3.2 billion reais (US$1 billion), is the lowest the country has seen in at least 12 years. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia: Immunological Memory: Innate, Adaptive and Beyond Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Scientist – Immune Oncology (Dana-Farber Cancer Institute) Research Technologist – Immunotherapy (STEMCELL Technologies Inc.) Scientist – Immunology (STEMCELL Technologies Inc.) Postdoctoral Researcher – Immunology (University of Luxembourg) Postdoctoral Fellowship – Tumor Immunology (UT Southwestern Medical Center) Postdoctoral Training Fellow – Immune Mechanisms (The Francis Crick Institute) Postdoctoral Fellow – Immunology (University of Rochester Medical Center) Postdoctoral Researcher – Development of Immune System (Lund University) Postdoctoral Fellow – Immunology Cell Based Assay (Turnstone Biologics Inc.) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|